Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

739 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines.
Vannice KS, Wilder-Smith A, Barrett ADT, Carrijo K, Cavaleri M, de Silva A, Durbin AP, Endy T, Harris E, Innis BL, Katzelnick LC, Smith PG, Sun W, Thomas SJ, Hombach J. Vannice KS, et al. Among authors: smith pg. Vaccine. 2018 Jun 7;36(24):3411-3417. doi: 10.1016/j.vaccine.2018.02.062. Epub 2018 Mar 7. Vaccine. 2018. PMID: 29525283 Free PMC article.
Long-term safety assessment of live attenuated tetravalent dengue vaccines: deliberations from a WHO technical consultation.
Live Dengue Vaccines Technical Consultation Reporting Group; Bentsi-Enchill AD, Schmitz J, Edelman R, Durbin A, Roehrig JT, Smith PG, Hombach J, Farrar J. Live Dengue Vaccines Technical Consultation Reporting Group, et al. Among authors: smith pg. Vaccine. 2013 May 28;31(23):2603-9. doi: 10.1016/j.vaccine.2013.03.038. Epub 2013 Apr 6. Vaccine. 2013. PMID: 23570986 Free PMC article.
Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine.
Wilder-Smith A, Hombach J, Ferguson N, Selgelid M, O'Brien K, Vannice K, Barrett A, Ferdinand E, Flasche S, Guzman M, Novaes HM, Ng LC, Smith PG, Tharmaphornpilas P, Yoon IK, Cravioto A, Farrar J, Nolan TM. Wilder-Smith A, et al. Among authors: smith pg. Lancet Infect Dis. 2019 Jan;19(1):e31-e38. doi: 10.1016/S1473-3099(18)30494-8. Epub 2018 Sep 5. Lancet Infect Dis. 2019. PMID: 30195995 Review.
Vaccine-attributable severe dengue in the Philippines.
Wilder-Smith A, Flasche S, Smith PG. Wilder-Smith A, et al. Among authors: smith pg. Lancet. 2019 Dec 14;394(10215):2151-2152. doi: 10.1016/S0140-6736(19)32525-5. Lancet. 2019. PMID: 31839188 No abstract available.
Does respiratory syncytial virus lower respiratory illness in early life cause recurrent wheeze of early childhood and asthma? Critical review of the evidence and guidance for future studies from a World Health Organization-sponsored meeting.
Driscoll AJ, Arshad SH, Bont L, Brunwasser SM, Cherian T, Englund JA, Fell DB, Hammitt LL, Hartert TV, Innis BL, Karron RA, Langley GE, Mulholland EK, Munywoki PK, Nair H, Ortiz JR, Savitz DA, Scheltema NM, Simões EAF, Smith PG, Were F, Zar HJ, Feikin DR. Driscoll AJ, et al. Among authors: smith pg. Vaccine. 2020 Mar 4;38(11):2435-2448. doi: 10.1016/j.vaccine.2020.01.020. Epub 2020 Jan 20. Vaccine. 2020. PMID: 31974017 Free PMC article. Review.
WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use.
Sparrow E, Adetifa I, Chaiyakunapruk N, Cherian T, Fell DB, Graham BS, Innis B, Kaslow DC, Karron RA, Nair H, Neuzil KM, Saha S, Smith PG, Srikantiah P, Were F, Zar HJ, Feikin D. Sparrow E, et al. Among authors: smith pg. Vaccine. 2022 Jun 9;40(26):3506-3510. doi: 10.1016/j.vaccine.2022.02.040. Epub 2022 Feb 17. Vaccine. 2022. PMID: 35184927 Free PMC article.
739 results